title: Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells.
abstract: Dendritic cell (DC)-based vaccination represents a promising approach to harness the specificity and potency of the immune system to combat cancer. Finding optimal strategies for tumor Ag preparation and subsequent pulsing of DC, as well as improving the immunogenicity of weak tumor Ags remain among the first challenges of this approach. In this report, we use a prophylactic vaccine consisting of DC loaded with whole, nonmanipulated B16-F10 melanoma cells that had been stressed by heat shock and gamma irradiation. Stressed B16-F10 cells underwent apoptosis and were internalized by bone marrow-derived DC during coculture. Surprisingly, coculture of DC with stressed B16-F10 undergoing apoptosis and necrosis did not induce DC maturation. However, a marked retardation in tumor growth was observed in C57BL/6 mice immunized using DC loaded with stressed B16-F10 cells and subsequently challenged with B16-F10 cells. Growth retardation was further increased by treating DC with LPS before in vivo administration. In vivo depletion studies revealed that both CD8(+) and CD4(+) T cells played a critical role in retarding tumor growth. In addition, treatment with anti-CD25 Ab to deplete CD4(+)CD25(+) regulatory T cells before DC vaccination considerably improved the effect of the vaccine and allowed the development of long-lived immune responses that were tumor protective. Our results demonstrate that depletion of regulatory T cells is an effective approach to improving the success of DC-based vaccination against weakly immunogenic tumors. Such a strategy can be readily applied to other tumor models and extended to therapeutic vaccination settings.
authors.affiliation: Malaghan Institute of Medical Research, Wellington South, New Zealand.
authors.forename: Simon J
authors.initials: SJ
authors.lastname: Prasad
authors.forename: Kathryn J
authors.initials: KJ
authors.lastname: Farrand
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Matthews
authors.forename: Joe H
authors.initials: JH
authors.lastname: Chang
authors.forename: Rebecca S
authors.initials: RS
authors.lastname: McHugh
authors.forename: Franca
authors.initials: F
authors.lastname: Ronchese
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D016923:Cell Death / Q000502:physiology; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D005434:Flow Cytometry; D005720:Gamma Rays; D006358:Hot Temperature; D008546:Melanoma, Experimental / Q000517:prevention & control*; D051379:Mice; D015375:Receptors, Interleukin-2 / Q000276:immunology; D013312:Stress, Physiological; D014407:Tumor Cells, Cultured
chemical_list: D019496:Cancer Vaccines; D015375:Receptors, Interleukin-2